Unlocking the true value of hits derived from HTS campaigns

About this lunch&learn session:

Drug discovery research is a complex endeavor that involves multiple stages. By providing the initial set of compounds with the potential to be developed, the hit identification phase, lays the groundwork for the next phases and significantly influences the success of the entire drug development process.

High-Throughput Screening (HTS) revolutionized drug discovery and was shown to be one of the most powerful tools for hit identification. However, an HTS campaign “per se” is typically not sufficient to support the selection and prioritization of the chemical matter identified. Therefore, focused follow-up activities become crucial for choosing the most promising hits.

In this lunch&learn session, we will focus on our “HIT QUALIFICATION” strategy as an effective and fundamental tool to unlock the true value of hits derived from HTS campaigns run in Axxam. We will talk about how biology and chemistry expertise can melt together to ensure a comprehensive validation, optimization, and prioritization of the best-suited molecules, thus enhancing the probability of downstream success and maximizing the value of this early yet impactful phase of drug discovery research.


Drug discovery; Hit identification; High-Throughput Screening (HTS); Integrated research; Hit qualification; Hit selection; Medicinal chemistry.

📅 Date: May 21 – 12-13:30

📍 Location: Switzerland Innovation Park Basel Area, Allschwil, Switzerland 

11:45   Door opening



12:00  Welcome

  •   Franziska Dornblut, Community Manager, Switzerland Innovation Park Basel Area


12:05   Unlocking the true value of hits derived from HTS campaigns

  • Iolanda Micco, Head of Discovery Chemistry


12:35  Q&A



12:45  Standing lunch sponsored by Axxam




Dr. Iolanda Micco is currently Head of Discovery Chemistry at Axxam in Italy, a leading provider of high-quality services for the identification of small molecules in drug discovery research. With a PhD in medicinal chemistry from the University of Siena, Italy, she boasts more than 15 years of international experience in pivotal management and strategic roles.

Prior to her current role, she directed medicinal chemistry activities at Scandion Oncology in Denmark and served as Associate Director of Chemistry and Alliances at Vipergen. Before her ventures in Denmark, she covered a teaching position in Singapore and led interdisciplinary drug discovery programs at Siena Biotech, in Italy.

Scroll to Top